Results for this period
Interim period (second quarter)1 April 2026–30 September 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Decline in sales of OEM culture media for China due to tighter regulations and the implementation of ordinances in China, decline in cell therapy-related demand due to fewer patients visiting Japan from China, and deterioration in the profitability of contract cell processing operations
None
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026–30 September 2026 |
| Net Sales | ¥1,947 million (YoY -22.2%) |
| Operating profit | ¥-92 million |
| Ordinary income | ¥-67 million |
| Profit attributable to owners of the parent | ¥-78 million |
| Net income per share | -¥15.37 |
| Equity ratio | End of the current fiscal period 64.9 / End of previous period 66.8 |
| Total assets | ¥9,047 million |
| Net assets | ¥5,874 million |
| Cash flows from operating activities | ¥253 million |
| Cash flows from investing activities | ¥-116 million |
| Cash flows from financing activities | ¥246 million |
| Cash and cash equivalents at end of period | ¥2,909 million |
| Full-year earnings forecast | Net Sales ¥4,009 million (YoY -18.8%) / Operating profit ¥-126 million / Ordinary income ¥-89 million / Net income ¥-103 million |
| Revision to Earnings Forecast | Net Sales Not disclosed → ¥4,009 million / Operating profit Not disclosed → ¥-126 million / Ordinary income Not disclosed → ¥-89 million / Net income Not disclosed → ¥-103 million |
| Annual Dividend Forecast | ¥10 → ¥5（-50.0%） |
| Segment revenue | Tissue Culture Business ¥920,154 thousand (YoY -28.2%) / Microbiology Business ¥617,582 thousand (YoY -10.0%) / Cell Processing Business ¥409,577 thousand (YoY -23.6%) |
| Segment profit | Tissue Culture Business ¥262,504 thousand (YoY -47.6%) / Microbiology Business ¥-31,545 thousand / Cell Processing Business ¥-59,301 thousand |
| Depreciation and amortization | ¥180,317 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income No / Extraordinary loss No |
| Disclosure regarding the going concern assumption | None |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies — companies / Company name Not disclosed / Excluded Number of companies — companies / Company name Not disclosed |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | Yes (for securities analysts and institutional investors) |
| Issued Shares at Period-End | 5,111,600 shares |
| Treasury Shares at Period-End | — shares |
| Factors Behind Changes in Business Performance | Decline in sales of OEM culture media for China due to tighter regulations and the implementation of ordinances in China, decline in cell therapy-related demand due to fewer patients visiting Japan from China, and deterioration in the profitability of contract cell processing operations |
Items this document does not state (7)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Cell therapy services stagnated due to tighter regulations and the implementation of ordinances in China, while demand for and sales of OEM culture media for China declined. Demand related to cell therapy also fell as the number of patients visiting Japan from China decreased. Profitability remained a challenge in the cell processing business, where contract cost of sales exceeded contract revenue.